MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:39Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Loop diuretics]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #243

2026-05-23T04:04:21Z

parser-claude batch MedTemplate pre-fill, Top 300 #243

New page

{{MedTemplate
| generic = Bumetanide
| brand = Bumex
| structure =
| classes = [[:Category:Loop_diuretics|Loop diuretic]]
| uses = <vote slug="chf-volume-overload-use">Volume overload in heart failure</vote>, <vote slug="pulmonary-edema-use">Acute pulmonary edema</vote>, <vote slug="hepatic-edema-use">Hepatic edema/ascites</vote>, <vote slug="ckd-edema-use">Edema in CKD</vote>
| starting_dose = 0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg
| preparations = 0.5, 1, 2 mg tablets; 0.25 mg/mL IV
| fda_max = ~10 mg/d typical
| pill_id =
| routes = Oral, IV, IM
| onset = PO 30-60 minutes; IV minutes
| duration = 4-6 hours
| halflife = 1-1.5 hours<ref name="bumex-label">FDA Prescribing Information, Bumex (bumetanide), Validus, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018225s033lbl.pdf</ref>
| bioavailability = ~80-95% (oral; more reliable than furosemide, comparable to torsemide)<ref name="bumex-label" />
| pregnancy = Avoid where possible; class concerns as for other loop diuretics.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="bumetanide-mech-claim">Bumetanide blocks the Na+/K+/2Cl- cotransporter (NKCC2) on the apical membrane of thick ascending limb cells, producing brisk natriuresis, kaliuresis, and free-water clearance; the more predictable oral bioavailability relative to furosemide makes it preferred where reliable absorption is essential.</vote> Ototoxicity, hypokalemic metabolic alkalosis, hyperuricemia, and gout flare are the characteristic class adverse effects. Use of bumetanide as a research tool to probe NKCC1-mediated chloride homeostasis in CNS conditions (epilepsy, autism) is an active investigational area<ref name="bumex-label" />.
}}

== References ==
<references />

Bumetanide - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #243